Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-436 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low dose ABT-436 | EXPERIMENTAL | ABT-436 or placebo administered once daily for 7 days. |
| Mid Dose ABT-436 | EXPERIMENTAL | ABT-436 or placebo administered once daily for 7 days. |
| High Dose ABT-436 | EXPERIMENTAL | ABT-436 or placebo administered once daily for 14 days. |
| Name | Type | Description |
|---|---|---|
| ABT-436 | DRUG | See Arm Description for details. |
| Placebo | DRUG | See Arm Description for details. |
Inclusion Criteria: 1. Age is between 18 and 55 years, inclusive. 2. If female, subject must be postmenopausal for at least two years or surgically sterile. 3. Females must have negative results for pregnancy tests prior to study drug administration. 4. If male, subject must be surgically sterile o...
ABT-436 is an investigational small molecule drug developed by Abbott Laboratories. It has been studied in a Phase 1 clinical trial in healthy adult volunteers to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. The specific disease indications for ABT-436 have not been disclosed.
ABT-436 is being developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker symbol ABT. Abbott conducted the Phase 1 study of ABT-436 in the United States.
ABT-436 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
ABT-436 has been evaluated in one completed Phase 1 trial, NCT01050127, titled A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults. The randomized, double-blind, controlled study enrolled 36 healthy adult participants in the United States.
ABT-436 has been studied in healthy adult volunteers rather than in patients with a specific disease. Its therapeutic indications have not been disclosed. The completed Phase 1 trial assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses in 36 healthy participants.